SiBone Q2: 15% Growth Looks Solid, but the Stock Will Judge the Payment Reset

SiBone's Q2 results improved, but reimbursement is still the real test

SiBone's second quarter was genuinely better, not just narratively better. The company delivered 15.2% Q2 revenue growth and reported positive adjusted EBITDA of $2.8 million. That does not settle the investment case, but it does show the business is improving while it continues to scale.

Adoption looks broader, not just louder

SiBone now has 1,715 active U.S. physicians, up 19%. For a device company, that matters because growth is usually driven by broader use across surgeons and hospitals, not by a small group of star users.

The bigger near-term variable is payment. CMS finalized a new MS-DRG family effective October 1 for complex spinal fusion procedures that incorporate iFuse Bedrock Granite in the in-patient setting. If reimbursement gets cleaner, SiBone may have an easier time turning revenue growth into earnings power.

Why investors should still stay measured

One quarter of positive EBITDA is a sign, not proof. SiBone is still a small, capital-consuming device company, and payment improvements only matter if surgeons keep using the system and hospitals keep supporting it.

Management also said SiBone submitted a 510(k) application for its third-breakthrough device, which helps reinforce the platform story. The key question now is whether SiBone can string together several quarters of steady growth after this improvement.

Operating momentum looks healthier than a single headline growth number

A clean quarter is more meaningful when the operating metrics also look solid.

Wider use and steadier productivity

For a device company, the basic test is simple: are more doctors using the product, and are existing accounts using it more? SiBone looks stronger on both fronts. The U.S. physician base reached 1,715 active U.S. physicians, up 19%, while trailing 12-month average revenue per territory increased 5%. More surgeons alone would not be enough; higher revenue per territory suggests the existing footprint is still deepening.

Margins and cash support the quality of the quarter

SiBone's gross margin was 79.5%, roughly in line with recent performance. That does not prove everything is smooth, but it is more consistent with durable demand than with aggressive discounting.

The company also narrowed its net loss by 33.6%, posted positive adjusted EBITDA of $2.8 million, and ended the quarter with $145.9 million in cash and equivalents. That balance sheet gives SiBone room to keep investing without immediate financing pressure.

What would make this quarter more convincing

The next few quarters matter. If physician adoption, territory productivity, margins, and cash flow continue to hold up, investors can be more confident that this is ordinary business momentum rather than a one-quarter pop.

Reimbursement is the catalyst, but it is not the same as adoption

SiBone already showed 20.2% 2025 revenue growth. That broader trend matters because it suggests demand was improving before Q2, not created by a single quarter.

Why the payment reset could help

In the outpatient setting, Granite already received Transitional Pass-Through payment status, which was designed to improve access and reduce payment friction. The new CMS MS-DRG family for the in-patient setting could do something similar there: make billing clearer and reduce uncertainty for hospitals using iFuse Bedrock Granite in complex spinal fusion cases.

Why the market may still hesitate

A payment update is not the same thing as sustained adoption. Even if reimbursement improves, the product still has to clear other real-world hurdles: hospital support, surgeon preference, and smooth integration into ongoing care pathways.

What to watch next

My checklist is straightforward:

• cleaner billing and reimbursement experience in the field
• continued hospital support for Granite
• steady use quarter after quarter
• progress on pipeline and regulatory filings without major delays

If those signals keep showing up, this quarter will look more like the start of a durable reset. If they do not, the market is more likely to treat it as a good quarter inside a still-proving story.